Poloxamer 407 is a thermoreversible hydrogel frequently used as a carrier for polymer formulations in delayed-absorption drug studies, with limited toxicity in young mice. We gave six 24-month-old C57BL/6nia male mice each a subcutaneous injection of polylactic acid (PLA)/polyglycolic acid (PGA) copolymer biodegradable microparticles mixed with poloxamer 407 at a dose of 1.1 g/kg and 6 g/kg, respectively. Six days following injection, the animals presented as mild to moderately lethargic and dehydrated, and were subsequently killed. Histological evaluation revealed moderate to marked necrotizing myocarditis and myocardial hemorrhage ([Figure 1](#F0001){ref-type="fig"}). Two additional cohorts of similarly aged C57BL/6nia mice received the same PLA/PGA microparticle formulation but without poloxamer 407, and showed no adverse clinical signs or lesions of necrotizing myocarditis. These observations suggest that aged C57BL/6nia mice can be sensitive to the cardiotoxic effects of poloxamer 407 under certain dose conditions. Figure 1.(A) Cardiac lesions in a 24-month-old C57BL/6nia male mouse treated with a poloxamer 407 hydrogel formulation were characterized by moderate to severe necrotizing myocarditis, histiocytes with abundant vacuolated cytoplasm, and hemorrhage. (B) For comparison, an essentially normal heart from an age- and gender-matched mouse not exposed to the poloxamer 407 formulation is shown. Myocardial necrosis and inflammation are not considered age-related lesions.
